SCHEMBL2442544

SCHEMBL2442544

CN(C)C(C)(C)C#CC(=O)S

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24127548 0.78 LMNA (0.39) LMNA
SCHEMBL23295353 0.78 LMNA (0.39) LMNA
Hydrochloric Acid SCHEMBL28721495 0.76 LMNA (0.38) LMNA
SCHEMBL28981936 0.76 LMNA (0.38) LMNA
SCHEMBL23894127 0.76 LMNA (0.38) LMNA
SCHEMBL23295530 0.74 MEN1 (0.38) LMNA
SCHEMBL28721135 0.73 LMNA (0.35) LMNA
SCHEMBL25039080 0.73 LMNA (0.35) LMNA
SCHEMBL23894132 0.71 LMNA (0.34) LMNA
SCHEMBL19259502 0.70 DNM1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149378-A1 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer ADVANCED BIODESIGN (FR) 2023-05-18 US claimed
EP-3362056-B1 AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER ADVANCED BIODESIGN (FR) 2021-02-24 EP claimed
EP-3362094-B1 COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE H2O2 LEVEL IN CANCER CELLS OF A SUBJECT ADVANCED BIODESIGN (FR) 2021-02-17 EP claimed
US-10406125-B2 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject ADVANCED BIODESIGN (FR) 2019-09-10 US claimed
US-20180303773-A1 COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A HARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE 2O2 LEVEL IN CANCER CELLS OF A SUBJECT ADVANCED BIODESIGN (FR) 2018-10-25 US claimed
US-20180296548-A1 AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER ADVANCEDC BIODESIGN (FR) 2018-10-18 US claimed
EP-3362094-A1 COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE H2O2 LEVEL IN CANCER CELLS OF A SUBJECT Advanced Biodesign (FR) 2018-08-22 EP claimed
EP-3362056-A1 AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER Advanced Biodesign (FR) 2018-08-22 EP claimed
WO-2017064241-A1 COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE H2O2 LEVEL IN CANCER CELLS OF A SUBJECT ADVANCED BIODESIGN (FR) 2017-04-20 WO claimed
WO-2017064247-A1 AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER ADVANCED BIODESIGN (FR) 2017-04-20 WO claimed
US-8026231-B2 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof CNRS (FR) 2011-09-27 US claimed
US-7078402-B2 Aminothiol ester compounds, pharmaceutical and cosmetics compositions containing same and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-07-18 US claimed
EP-1296946-B1 AMINOTHIOLESTER COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES THEREOF GALDERMA RES & DEV (FR) 2004-04-21 EP claimed
US-20030181443-A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof ADVANCED BIODESIGN (FR) 2003-09-25 US claimed
US-20230149378-A1 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer ADVANCED BIODESIGN (FR) 2023-05-18 US disclosed
US-20230149378-A1 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer ADVANCED BIODESIGN (FR) 2023-05-18 US disclosed
EP-3833657-A1 AMINOTHIOLESTER COMPOUNDS AND USES THEREOF Advanced Biodesign (FR) 2021-06-16 EP disclosed
US-20070032476-A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof CNRS - CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2007-02-08 US disclosed
US-7078402-B2 Aminothiol ester compounds, pharmaceutical and cosmetics compositions containing same and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-07-18 US disclosed
US-20030181443-A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof ADVANCED BIODESIGN (FR) 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296548-A1 AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER SHMT2, CTH, MGMT LMNA 4874/4885
US-20180303773-A1 COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A HARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE 2O2 LEVEL IN CANCER CELLS OF A SUBJECT BHMT2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SHMT2 LMNA 4786/4885
US-10406125-B2 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CTH, MGMT LMNA 4876/4885
US-20070032476-A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof AADAT, ALDH7A1, AASDHPPT LMNA 2439/4885
US-20030181443-A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof AADAT, ALDH7A1, TYR LMNA 2556/4885
US-20230149378-A1 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer SHMT2, CTH, MGMT LMNA 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.